Superior vena cava

AngioDynamics Receives FDA Breakthrough Device Designation for the AngioVac System for the Non-Surgical Removal of Right Heart Vegetation

Retrieved on: 
Tuesday, August 15, 2023

The FDA Breakthrough Device designation is designed to help patients gain timely access to medical devices that may provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions for which no approved or cleared alternatives exist.

Key Points: 
  • The FDA Breakthrough Device designation is designed to help patients gain timely access to medical devices that may provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions for which no approved or cleared alternatives exist.
  • The system allows for the removal of thrombus and embolic material while minimizing blood loss via a recirculation of blood through the AngioVac extracorporeal (venovenous) bypass circuit.
  • Target vessels for the thrombus/embolus extraction include, but are not limited to, the iliofemoral vein, Inferior Vena Cava (IVC), Superior Vena Cava (SVC) and Right Heart.
  • Under the Breakthrough Device designation, AngioDynamics will engage with the FDA to achieve this new expanded indication for the non-surgical removal of vegetation from the right heart.

BIOMODEX Expands Product Offerings with Innovative Transseptal Puncture Training Solution

Retrieved on: 
Thursday, January 14, 2021

BOSTON, Jan. 14, 2021 /PRNewswire/ -- BIOMODEX , a pioneering digital health company that offers a unique and enhanced 3D printed solution for patient specific rehearsal and physician training, today announced the launch of the company's new Transseptal Puncture Training Solution.

Key Points: 
  • BOSTON, Jan. 14, 2021 /PRNewswire/ -- BIOMODEX , a pioneering digital health company that offers a unique and enhanced 3D printed solution for patient specific rehearsal and physician training, today announced the launch of the company's new Transseptal Puncture Training Solution.
  • Biomodex's Transseptal Training Cartridges are 3D-printed using Biomodex's INVIVOTECH and ECHOTECH technologies, which integrates multiple advanced materials.
  • Reusable cartridge (inferior and superior vena cava, right atrium, aorta and mitral annulus)
    Watch this video about the Biomodex Transseptal Puncture Training system.
  • Biomodex has successfully commercialized several products for neurovascular and structural heart applications and is fast expanding its product portfolio through the application of its core technologies.

Global Vena Cava Clips and Filters Market 2019-2023| 11% CAGR Projection Over the Next Five Years | Technavio

Retrieved on: 
Monday, May 27, 2019

The global vena cava clips and filters market is expected to post a CAGR of more than 11% during the period 2019-2023, according to the latest market research report by Technavio .

Key Points: 
  • The global vena cava clips and filters market is expected to post a CAGR of more than 11% during the period 2019-2023, according to the latest market research report by Technavio .
  • View the full release here: https://www.businesswire.com/news/home/20190527005082/en/
    Technavio has published a new market research report on the global vena cava clips and filters market from 2019-2023.
  • This global vena cava clips and filters market 2019-2023 research report also analyzes other significant trends and market drivers that will affect market growth over the forecast period.
  • Global vena cava clips and filters market: Segmentation analysis
    This vena cava clips and filter market analysis segments the global vena cava clips and filters market by product (interior vena cava filters (IVCFs), and superior vena cava filters (SVCFs)) and geographic regions (North America, Europe, Asia, and ROW).